A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

Summary

This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.

Timeline

Start

2024-05-27

Primary completion

2026-12

Completion

2027-07

Drugs

Indications